FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and can be used for preparing a drug for relieving skeletal muscle loss or skeletal muscle function associated with amyotrophic lateral sclerosis (ALS). That is ensured by introducing levosimendan or its active metabolite (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl phenyl]-acetamide (II) or pharmaceutically acceptable salts. Also disclosed is a method of facilitating loss of skeletal muscle or skeletal muscle function.
EFFECT: group of inventions enables relieving loss of skeletal muscle strength or skeletal muscle function in patients with amyotrophic lateral sclerosis.
8 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF SULPHATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1N-BENZO[D]IMIDAZOL-2-AMINE AND THEIR SOLVATES FOR TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR DISEASES | 2021 |
|
RU2814327C1 |
| THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 2013 |
|
RU2655811C2 |
| USE OF TRYPTOPHAN METABOLITES FOR THE TREATMENT OF MUSCULAR ATROPHY | 2017 |
|
RU2806346C2 |
| NEW COMBINATIONS OF NERAMEXANE FOR TREATING NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2432161C1 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOPHAGY OF MOTOR NEURONS AND USE THEREOF | 2012 |
|
RU2585372C1 |
| TREATMENT METHOD INCLUDING ORAL OR GASTRIC EXCRETION OF EDARAVON | 2018 |
|
RU2761967C2 |
| USE OF BENZOATE FOR TREATMENT OF DISORDERS OF CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2780450C2 |
| TETRAHYDROISOQUINOLINE DERIVATIVES | 2017 |
|
RU2743424C2 |
| INJECTION OF DEUTERATED CFTR AMPLIFIERS | 2016 |
|
RU2761344C2 |
| MEANS FOR TREATMENT OF VIOLATIONS INVOLVING RIANODIN RECEPTORS MODULATION | 2013 |
|
RU2644350C2 |
